NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and Sengenics said today that they have formed a partnership to identify and validate auto-antibody signatures for the early detection of cancers.

The collaboration will use protein microarray technology from Senegenics' strategic partner, Oxford Gene Technology, and will focus initially on gastric and breast cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.